NAPSRX EXAM GUIDE2026 LATEST UPDATE QUESTIONS AND
CORRECT VERIFIED ANSWERS ALREADY GRADED A+
percentage fee - ANS-the fee that the dispenser pays the wholesaler for distribution.
chronic reaction - ANS-a reaction that persists for a long time.
delayed reaction - ANS-a reaction that takes some time to develop.
clinical effect - ANS-the response produced by a medication.
noncompliance - ANS-a patient forgetting to take a drug at a specified time of day.
average circulation time of blood - ANS-about 5 to 10 minutes depending on the patient's age
and health conditions.
pharmaceutical selling - ANS-involves decisions-makers, consumers, and payers usually being
the same entity.
primary wholesale distributors - ANS-buy most of their drugs from manufacturers.
Office of the Inspector General (OIG) - ANS-an arm of the Department of Health and Human
Services.
prescribing considerations - ANS-the severity of the disorder being treated and the effect it has
on the patient's quality of life.
,generic names assignment - ANS-assigned by the United States Adopted Name Council.
drug expiration date - ANS-drugs can be used 7-90 days beyond their expiration date
depending on the type of drug and its therapeutic class.
kidney excretion - ANS-a drug must be water-soluble and not bind too tightly to proteins in
the bloodstream.
clinical trial initiation - ANS-initiated and financed by a sponsor.
chemical name - ANS-describes the atomic or molecular structure of a drug.
PhRMA Code - ANS-regulates the acceptability of pharmaceutical sales reps taking physicians
to events.
margin fee - ANS-a type of fee related to the profit margin in distribution.
recharge - ANS-a term related to the replenishment of stock.
standard fee - ANS-a typical fee charged for services.
upcharge - ANS-an additional charge added to the standard fee.
idiosyncratic reaction - ANS-a reaction that is unusual and specific to an individual.
federally funded research condition - ANS-a research condition supported by government
funding.
,maximum dosage effect - ANS-the effect produced by administering the maximum allowable
dosage of a medication.
Hatch-Waxman Act - ANS-The most significant drug-related legislation affecting the
pharmaceutical industry since 1962.
toxicity - ANS-The extent, quality, or degree to which a substance is poisonous or harmful to
the body.
efficacy - ANS-The degree to which a medication produces a therapeutic effect.
electronic prescribing - ANS-The most important benefit is safety.
FDA regulation of generic drugs - ANS-The FDA regulates generic drugs always.
Phase II trials - ANS-The phase of trials that largely determines the clinical dose.
inactivated vaccines - ANS-They have a more stable shelf life compared to attenuated vaccines.
ischemia - ANS-A low supply of oxygen due to low blood flow.
prescription drug marketing - ANS-The two main types are (1) professional physician
promotions and (2) direct-to-consumer advertising.
subcutaneous injections - ANS-The site of delivery is fatty tissue beneath the surface of the
skin.
, pharmaceutical package insert - ANS-The Description section must contain the proprietary
name and the established name.
pharmacokinetics - ANS-The study of a medication's effects as it travels through the body.
likeability factor - ANS-Customers purchase products from people they like, trust, and respect.
penicillin's primary mechanism of action - ANS-It disturbs bacterial cell wall synthesis.
U.S. healthcare marketplace changes - ANS-Managed care has been increasingly replaced by
more patient-centered approaches.
pharmaceutical marketing - ANS-It encourages patients to take more active roles in their
healthcare.
immunosuppressive agents - ANS-They increase the risk of infection.
EGFR inhibitors - ANS-They are antineoplastics.
advantage of inactivated vaccines - ANS-Inactivated vaccines are less expensive to prepare.
clinical dose determination - ANS-Phase II trials largely determine the clinical dose.
risk of rejection - ANS-Immunosuppressive agents reduce the risk of rejection of foreign bodies.
CORRECT VERIFIED ANSWERS ALREADY GRADED A+
percentage fee - ANS-the fee that the dispenser pays the wholesaler for distribution.
chronic reaction - ANS-a reaction that persists for a long time.
delayed reaction - ANS-a reaction that takes some time to develop.
clinical effect - ANS-the response produced by a medication.
noncompliance - ANS-a patient forgetting to take a drug at a specified time of day.
average circulation time of blood - ANS-about 5 to 10 minutes depending on the patient's age
and health conditions.
pharmaceutical selling - ANS-involves decisions-makers, consumers, and payers usually being
the same entity.
primary wholesale distributors - ANS-buy most of their drugs from manufacturers.
Office of the Inspector General (OIG) - ANS-an arm of the Department of Health and Human
Services.
prescribing considerations - ANS-the severity of the disorder being treated and the effect it has
on the patient's quality of life.
,generic names assignment - ANS-assigned by the United States Adopted Name Council.
drug expiration date - ANS-drugs can be used 7-90 days beyond their expiration date
depending on the type of drug and its therapeutic class.
kidney excretion - ANS-a drug must be water-soluble and not bind too tightly to proteins in
the bloodstream.
clinical trial initiation - ANS-initiated and financed by a sponsor.
chemical name - ANS-describes the atomic or molecular structure of a drug.
PhRMA Code - ANS-regulates the acceptability of pharmaceutical sales reps taking physicians
to events.
margin fee - ANS-a type of fee related to the profit margin in distribution.
recharge - ANS-a term related to the replenishment of stock.
standard fee - ANS-a typical fee charged for services.
upcharge - ANS-an additional charge added to the standard fee.
idiosyncratic reaction - ANS-a reaction that is unusual and specific to an individual.
federally funded research condition - ANS-a research condition supported by government
funding.
,maximum dosage effect - ANS-the effect produced by administering the maximum allowable
dosage of a medication.
Hatch-Waxman Act - ANS-The most significant drug-related legislation affecting the
pharmaceutical industry since 1962.
toxicity - ANS-The extent, quality, or degree to which a substance is poisonous or harmful to
the body.
efficacy - ANS-The degree to which a medication produces a therapeutic effect.
electronic prescribing - ANS-The most important benefit is safety.
FDA regulation of generic drugs - ANS-The FDA regulates generic drugs always.
Phase II trials - ANS-The phase of trials that largely determines the clinical dose.
inactivated vaccines - ANS-They have a more stable shelf life compared to attenuated vaccines.
ischemia - ANS-A low supply of oxygen due to low blood flow.
prescription drug marketing - ANS-The two main types are (1) professional physician
promotions and (2) direct-to-consumer advertising.
subcutaneous injections - ANS-The site of delivery is fatty tissue beneath the surface of the
skin.
, pharmaceutical package insert - ANS-The Description section must contain the proprietary
name and the established name.
pharmacokinetics - ANS-The study of a medication's effects as it travels through the body.
likeability factor - ANS-Customers purchase products from people they like, trust, and respect.
penicillin's primary mechanism of action - ANS-It disturbs bacterial cell wall synthesis.
U.S. healthcare marketplace changes - ANS-Managed care has been increasingly replaced by
more patient-centered approaches.
pharmaceutical marketing - ANS-It encourages patients to take more active roles in their
healthcare.
immunosuppressive agents - ANS-They increase the risk of infection.
EGFR inhibitors - ANS-They are antineoplastics.
advantage of inactivated vaccines - ANS-Inactivated vaccines are less expensive to prepare.
clinical dose determination - ANS-Phase II trials largely determine the clinical dose.
risk of rejection - ANS-Immunosuppressive agents reduce the risk of rejection of foreign bodies.
